PD-L1 expression is associated with FOXP3+ regulatory T-Cell infiltration of soft tissue sarcoma and poor patient prognosis

Journal of Cancer

Volumn 8, Issue 11, 2017, Pages 2018-2025

  Que, Yi ^a   Xiao, Wei ^a   Guan, Yuan xiang ^a   Liang, Yao ^a   Yan, Shu Mei ^a   Chen, Huo Ying ^a   Li, Qiao Qiao ^a   Xu, Bu Shu ^a   Zhou, Zhi Wei ^a   Zhang, Xing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

FOXP3+; PD L1; Prognosis; Soft tissue sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; AGED; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CHINA; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRITON TUMOR; NNDIFFERENTIATED PLEOMORPHIC SARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RADICAL RESECTION; REGULATORY T LYMPHOCYTE; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

EID: 85025443044     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.18683     Document Type: Article

References (38)

1. Bannasch H, Eisenhardt SU, Grosu AL, Heinz J, Momeni A, Stark GB. The diagnosis and treatment of soft tissue sarcomas of the limbs. Deutsches Arzteblatt international. 2011; 108: 32-8.
2. Daigeler A, Zmarsly I, Hirsch T, Goertz O, Steinau HU, Lehnhardt M, et al. Long-term outcome after local recurrence of soft tissue sarcoma: a retrospective analysis of factors predictive of survival in 135 patients with locally recurrent soft tissue sarcoma. British journal of cancer. 2014; 110: 1456-64.
3. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21: 2719-25.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010; 363: 711-23.
5. Zustovich F, Cartei G, Dal Bianco M, De Zorzi L, Ceravolo R, Zovato S, et al. A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2006; 17 Suppl 5: v133-6.
6. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015; 373: 123-35.
7. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. Journal of immunology (Baltimore, Md: 1950). 2005; 175: 1586-92.
8. Hatam LJ, Devoti JA, Rosenthal DW, Lam F, Abramson AL, Steinberg BM, et al. Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18: 1925-35.
9. Wenjin Z, Chuanhui P, Yunle W, Lateef SA, Shusen Z. Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC gastroenterology. 2012; 12: 109.
10. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. European journal of cancer. 2013; 49: 2233-42.
11. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori. 2012; 98: 751-5.
12. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104: 3360-5.
13. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PloS one. 2013; 8: e82870.
14. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human pathology. 2015; 46: 357-65.
15. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. International immunology. 2004; 16: 1643-56.
16. Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature reviews Immunology. 2007; 7: 305-10.
17. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature immunology. 2003; 4: 330-6.
18. Jang TJ. Progressive Increase of Regulatory T Cells and Decrease of CD8+ T Cells and CD8+ T Cells/Regulatory T Cells Ratio during Colorectal Cancer Development. Korean journal of pathology. 2013; 47: 443-51.
19. Pan XD, Mao YQ, Zhu LJ, Li J, Xie Y, Wang L, et al. Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice. Chinese medical journal. 2012; 125: 2004-11.
20. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. The Journal of experimental medicine. 2009; 206: 3015-29.
21. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105: 9331-6.
22. Hou J, Yu Z, Xiang R, Li C, Wang L, Chen S, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Experimental and molecular pathology. 2014; 96: 284-91.
23. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, et al. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta histochemica. 2014; 116: 1163-8.
24. Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, et al. PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer. 2016; 7: 784-93.
25. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine. 2002; 8: 793-800.
26. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011; 117: 2192-201.
27. Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2014; 25: 2178-84.
28. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer immunology research. 2014; 2: 361-70.
29. Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Medical oncology. 2016; 33: 93.
30. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC cancer. 2016; 16: 434.
31. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer immunology research. 2014; 2: 690-8.
32. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Current topics in microbiology and immunology. 2011; 350: 17-37.
33. Burton OT, Zaccone P, Phillips JM, De La Pena H, Fehervari Z, Azuma M, et al. Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice. Journal of immunology (Baltimore, Md: 1950). 2010; 185: 2754-62.
34. Zhao Y, Huang Z, Qi M, Lazzarini P, Mazzone T. Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell. Immunology letters. 2007; 108: 78-87.
35. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunological reviews. 2010; 236: 219-42.
36. Amarnath S, Costanzo CM, Mariotti J, Ullman JL, Telford WG, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS biology. 2010; 8: e1000302.
37. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer research. 2008; 68: 5432-8.
38. Maki RG, Jungbluth AA, Gnjatic S, Schwartz GK, D'Adamo DR, Keohan ML, et al. A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma. 2013; 2013: 168145.